Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Express Scripts
Moodys
Colorcon
Medtronic

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed Document No. Description Snippet Link To Document
2020-01-03 299 Notice (Other) invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399, 514 (“the ’514 patent”) (collectively… the “patents-in-suit”) and/or show the state of the art relative to the asserted patents. … Patents and File Histories Date of Issue/ Patent/Patent… Date of Issue/ Patent/Patent Publication Country of Publication…of the Asserted Patents All patentees, applicants, and authors of the patents and publications External link to document
2020-01-09 308 Other Document 13:23-14:12 21:15-17 22:10-14 28:10-29:15 29:19-23 30:13-18 30:20-31:19 …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) External link to document
2020-01-16 323 Other Document asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document External link to document
2020-01-16 326 Other Document 13:23-14:12 21:15-17 22:10-14 28:10-29:15 V, P, LF, In, R 29:19-23 30:13…30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) External link to document
2020-01-21 328 Attachment Ex. A - proposed Reply Brief Term ’514 patent U.S. Patent No. 8,399,514 (issued Mar. 19, 2013) …’s reliance on a vague citation to the ’514 patent prosecution, IPR, and interference proceedings …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) External link to document
2020-02-08 358 Transcript 4 Number 6. And so is this U.S. patent 8,399,514? 5 A. That is what it says on the …reading the patent 2 specification. And it was submitted both in the patent office 3… who said that in also the 5 patent office to get the patent allowed, and it's the viewpoint…artisan, thinking that the patent would not 8 work, reads the patent specification and doesn'…in the 13 patent. 14 MS. BLOODWORTH: It's not in the patent that it would External link to document
2020-04-03 377 Response in Opposition to Motion stomach acid.’” Id. at 1374 (quoting U.S. Patent No. 6,926,907, a patent-in-suit). In contradiction to this…new patent claims to the ’514 patent application, as is permitted and often happens during patent …the PTO found Biogen’s patent claims patentable and issued the ’514 patent, and in doing so never …Multiple sclerosis ’514 patent U.S. Patent No. 8,399,514 DMF …evidence, was that Biogen’s U.S. Patent No. 8,399,514 (“the ’514 patent”) (JTX2000) lacks written description External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Merck
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.